Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Pharmaceutical Glass Co's EBIT per Share for the
three
months ended in Mar. 2026 was ¥0.36.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.21.
During the past 12 months, the average EBIT per Share Growth Rate of Shandong Pharmaceutical Glass Co was -13.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 6.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 5.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 12.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Shandong Pharmaceutical Glass Co's EBIT per Share or its related term are showing as below:
SHSE:600529'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -3.8 Med: 8.4 Max: 29.3
Current: 6.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Shandong Pharmaceutical Glass Co was 29.30% per year. The lowest was -3.80% per year. And the median was 8.40% per year.
SHSE:600529's 3-Year EBIT Growth Rate is ranked better than 56.4% of 328
companies
in the Packaging & Containers industry
Industry Median: 2.95
vs SHSE:600529: 6.60
Shandong Pharmaceutical Glass Co (SHSE:600529) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Shandong Pharmaceutical Glass Co EBIT per Share Related Terms
Shandong Pharmaceutical Glass Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Pharmaceutical Glass Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Pharmaceutical Glass Co (SHSE:600529) has a EBIT per Share of ¥1.21 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shandong Pharmaceutical Glass Co and its competitors. According to the industry distribution chart, Shandong Pharmaceutical Glass Co ranks #143 out of 328 companies in the Packaging & Containers industry, placing it in the top 43.6%.
Is Shandong Pharmaceutical Glass Co's EBIT per Share too high?
Shandong Pharmaceutical Glass Co's current EBIT per Share is ¥1.21. Based on the distribution chart, Shandong Pharmaceutical Glass Co ranks #143 out of 328 companies in the Packaging & Containers industry, which is above the industry midpoint. Overall, Shandong Pharmaceutical Glass Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Pharmaceutical Glass Co's EBIT per Share compare to SW and PKG?
According to the Packaging & Containers industry distribution chart, Shandong Pharmaceutical Glass Co ranks #143 out of 328 companies for EBIT per Share. This puts Shandong Pharmaceutical Glass Co in the upper half of its industry. The industry median EBIT per Share is 2.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Packaging & Containers company?
The median EBIT per Share among Packaging & Containers companies is 2.95, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shandong Pharmaceutical Glass Co and its competitors. For the Packaging & Containers industry, the median EBIT per Share is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Pharmaceutical Glass Co's current EBIT per Share is ¥1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Pharmaceutical Glass Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co (SHSE:600529) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥24.40, compared to a current price of ¥19.61 — trading 19.6% below its estimated fair value. The current EBIT per Share is ¥1.21. Shandong Pharmaceutical Glass Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Shandong Pharmaceutical Glass Co (SHSE:600529), the current EBIT per Share is ¥1.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Pharmaceutical Glass Co (SHSE:600529) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co stock appears to be undervalued.
The current stock price of ¥19.61 is trading 19.6% below its estimated GF Value™ of ¥24.40.
GuruFocus considers Shandong Pharmaceutical Glass Co to be Modestly Undervalued.
Key valuation signals for SHSE:600529:
EBIT per Share: ¥1.21
GF Value™: ¥24.40 vs. price of ¥19.61 (19.6% below fair value)
No single metric tells the full story. See the SHSE:600529 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Pharmaceutical Glass Co Business Description
Shandong Pharmaceutical Glass Co Ltd is a pharmaceutical glass packaging product company. Its pharmaceutical glass packaging products and butyl rubber series products which service object of pharmaceutical, food, daily necessities industries. The products include for moulded injection vial for antibiotics series, tubular glass vial series, amber glass bottle series, neutral borosilicate glass bottle series, infusion bottle series, cosmetic bottles series, food bottles series, butyl rubber stopper series, prefillable syringes series, and aluminum-plastic cap series.
90GF Score
Get the complete analysis for SHSE:600529
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600529 has been successfully added to your 
